8-K: CareDx Q3 2025 Revenue Jumps 21%, Raises Full-Year Outlook

CareDx, Inc. reported strong third-quarter 2025 financial results with total revenue increasing 21% year-over-year to $100.1 million and raised its full-year 2025 revenue and adjusted EBITDA guidance.

Summary

• Total revenue for Q3 2025 was $100.1 million, marking a 21% increase year-over-year.
• Testing services revenue grew 19% year-over-year to $72.2 million, with testing services volume reaching approximately 50,300, up 13% year-over-year.
• GAAP net income for Q3 2025 was $1.7 million, a significant improvement compared to a GAAP net loss of $10.6 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $15.3 million, more than double the $6.9 million reported in Q3 2024.
• Cash, cash equivalents, and marketable securities stood at $194.2 million as of September 30, 2025, after a $25.6 million share repurchase during the quarter, with no outstanding debt.
• Full-year 2025 revenue guidance was raised to a range of $372 million to $376 million, up from the previously disclosed range of $367 million to $373 million.
• Full-year 2025 adjusted EBITDA guidance was also raised to a range of $35 million to $39 million, from the prior range of $29 million to $33 million.
• Suresh Gunasekaran, President and CEO of UCSF Health, was appointed to the Board of Directors.
• Jeff Teuteberg, MD, was appointed as Chief Medical Officer.
• The second SHORE study was published, validating AlloSure Heart as a reliable biomarker for detecting antibody-mediated rejection (AMR) in heart transplant patients.
• HistoMap Kidney, a tissue-based gene expression profiler, was introduced.
• The first Epic Aura implementation was completed, with approximately 20 implementations anticipated by year-end 2025.
• AlloSeq Tx11, a next-generation HLA typing solution, was launched.
• Score 7.0, modernized analysis software for QTYPE, was introduced.

Sentiment

Score: 9

Explanation: The company reported record-setting financial results with significant year-over-year revenue growth, a return to GAAP profitability, and a substantial increase in Adjusted EBITDA. The upward revision of full-year guidance for both revenue and Adjusted EBITDA, coupled with strategic business highlights and product innovations, indicates very strong positive momentum and a robust outlook.

Positives

• Total revenue increased by a robust 21% year-over-year to $100.1 million in Q3 2025.
• The company achieved GAAP net income of $1.7 million in Q3 2025, a significant turnaround from a GAAP net loss of $10.6 million in the prior year's quarter.
• Adjusted EBITDA more than doubled to $15.3 million in Q3 2025, demonstrating improved operational efficiency and profitability.
• Full-year 2025 revenue guidance was raised to $372 million to $376 million, indicating strong confidence in continued growth.
• Full-year 2025 adjusted EBITDA guidance was also raised to $35 million to $39 million, reflecting an improved outlook for profitability.
• Testing services volume grew by 13% year-over-year to 50,300, showing increased adoption of core services.
• The company maintains a strong cash position with $194.2 million in cash, cash equivalents, and marketable securities, and no outstanding debt.
• Strategic appointments of Suresh Gunasekaran to the Board and Jeff Teuteberg, MD, as Chief Medical Officer strengthen leadership and clinical expertise.
• Continued innovation with the publication of the second SHORE study validating AlloSure Heart, and the introduction of HistoMap Kidney, AlloSeq Tx11, and Score 7.0.

Negatives

• Accrued litigation settlement expense of $20.25 million was recorded as of September 30, 2025, which represents a material financial obligation.

Risks

• General economic and market factors could adversely affect financial results.
• Global economic and marketplace uncertainties pose potential challenges.
• Actual results could differ materially from projections due to numerous risks and uncertainties beyond the company's control, as detailed in previous SEC filings, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company raised its full-year 2025 revenue guidance to a range of $372 million to $376 million and its adjusted EBITDA guidance to a range of $35 million to $39 million. It also anticipates initiating approximately 20 Epic Aura implementations by year-end 2025.

Management Comments

• "We achieved record-setting third quarter 2025 financial results, a testament to our market leadership that has been established through a deep commitment to innovation and transplant patient care." John W. Hanna, President and CEO of CareDx.
• "Our strategy to extend that leadership and deliver long-term profitable growth is guided by putting our customers at the center of everything we do, and we believe that strategy is working." John W. Hanna, President and CEO of CareDx.

Industry Context

CareDx operates as a leading precision medicine company specializing in healthcare solutions for transplant patients. The strong Q3 2025 results, including significant revenue growth and a return to GAAP profitability, suggest the company is effectively capitalizing on the demand for advanced diagnostic and digital solutions in the transplant sector. Its continuous product innovation, such as AlloSure Heart validation and the introduction of HistoMap Kidney and AlloSeq Tx11, aligns with broader industry trends towards personalized medicine and integrated digital health platforms, reinforcing its market leadership in a specialized and high-value segment of healthcare.

Comparison to Industry Standards

• The filing highlights CareDx's 'market leadership' in precision medicine for transplant patients but does not provide specific comparable companies, projects, or industry benchmarks to assess its performance against global standards.
• The company's focus on genomics-based information and digital healthcare solutions positions it within a growing segment of the healthcare industry, but without specific competitor data, a direct comparison of results is not feasible based solely on this filing.

Management Changes

Corporate Governance

Legal Proceedings

• Accrued litigation settlement expense of $20.25 million was recorded as of September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, raised guidance, and a share repurchase program, indicating enhanced shareholder value.
• Patients and Caregivers: Positive impact through continued innovation in precision medicine solutions, including new diagnostic tools and validated biomarkers, aimed at improving transplant patient care.
• Customers (Healthcare Providers): Positive impact from new product launches (HistoMap Kidney, AlloSeq Tx11, Score 7.0) and digital solution implementations (Epic Aura), offering more precise and timely decision-making tools.
• Employees: Generally positive due to company growth and strategic advancements, although non-GAAP adjustments mention 'transformational initiative costs' and 'restructuring costs' which could imply internal organizational changes.

Next Steps

• Anticipate initiating approximately 20 Epic Aura implementations by year-end 2025.
• Inform the final draft of the LCD policy, following the submission of an extensive, evidence-based comment letter.

Key Dates

Recommendation

The company's Q3 2025 results demonstrate exceptional financial performance, including a 21% year-over-year revenue increase, a significant turnaround to GAAP net income, and a doubling of Adjusted EBITDA. The upward revision of full-year 2025 guidance for both revenue and Adjusted EBITDA signals strong management confidence and robust future prospects. Strategic appointments and continuous product innovation further solidify its market leadership in the specialized and growing field of precision transplant medicine. These factors collectively indicate a strong growth trajectory and improved profitability, making it a highly attractive investment.

Keywords

Transplant, Precision Medicine, Genomics, Healthcare Solutions, Financial Results, Q3 2025, Revenue, EBITDA, Guidance, CareDx, CDNA, AlloSure Heart, HistoMap Kidney, AlloSeq Tx11, Epic Aura